Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | DNM1 | Q05193 | 12/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | RAD52 | P43351 | 2/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6238905 | 1.00 | HTT (0.60) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL6238274 | 1.00 | HTT (0.60) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL16604562 | 0.92 | HTT (0.60) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL10932296 | 0.92 | HTT (0.60) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL6234110 | 0.92 | HTT (0.60) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL10933953 | 0.92 | HTT (0.60) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL10937742 | 0.92 | HTT (0.60) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL6236875 | 0.92 | HTT (0.60) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL6236479 | 0.92 | HTT (0.60) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL10975956 | 0.92 | HTT (0.60) | HTTDNM1KMT2AHSP90AA1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0756633-B1 | METHOD AND KITS FOR PROCESSING MYCOBACTERIA AND MYCOLIC ACID CONTAINING BACTERIA | INTEGRATED RES TECHNOLOGY LLC (US) | 2005-06-08 | — | — | EP | claimed |
| CN-1125880-C | Method for processing mycobacteria | INTEGRATED RES TECH PLC (US) | 2003-10-29 | — | — | CN | claimed |
| CN-1150460-A | Method for processing mycobacteria | CORNING CLINICAL LAB INC (US) | 1997-05-21 | — | — | CN | claimed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
| US-20160016981-A1 | AMINO- OR AMMONIUM-CONTAINING SULFONIC ACID, PHOSPHONIC ACID AND CARBOXYLIC ACID DERIVATIVES AND THEIR MEDICAL USE | GLYCOREGIMMUNE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-6004771-A | EXTRACTED MYCOBACTERIAL SAMPLE IS SUITABLE FOR DETECTION BY CULTURE AND AMPLIFICATION | INTEGRATED RESEARCH TECHNOLOGY, LLC (US) | 1999-12-21 | — | — | US | disclosed |
| US-5658749-A | DECREASING THE BUOYANCY OF MICROORGANISMS CONTAINING MYCOLIC ACID-LIKE STRUCTURES IN THE OUTER MEMBRANE USING A SOLUTION OF AN SB-18-LIKE OR ROD-LIKE DETERGENT; AMPHOTERIC SURFACTANTS; MEDICAL DIAGNOSIS; CULTURES; AMPLIFICATION | CORNING CLINICAL LABORATORIES, INC. (US) | 1997-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016981-A1 | AMINO- OR AMMONIUM-CONTAINING SULFONIC ACID, PHOSPHONIC ACID AND CARBOXYLIC ACID DERIVATIVES AND THEIR MEDICAL USE | AADAT, AASDHPPT, ASS1 | HTT 3289/4885DNM1 2791/4885KMT2A 2089/4885 |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | HTT 4263/4885DNM1 3773/4885KMT2A 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.